Drug intelligence / Profile preview

SPARC1103

Development stage: Unknown
Lead developer: SPARC
Modality: Small Molecules
Administration: Oral, Intrathecal

Overview

SPARC1103 is an investigational drug developed for the treatment of spasticity. It has been evaluated in clinical trials for its efficacy and safety in subjects with spasticity, but detailed public information about its chemical structure, mechanism of action, or formulation is not available from current sources. The drug was studied in a clinical trial sponsored by Sun Pharma Advanced Research Company Limited (SPARC), with the trial completed and results reported. The specific modality, active ingredient, and mechanistic details have not been disclosed in publicly accessible databases or literature as of June 2025[3][6].

Other names: Baclofen GRSBaclofen Gastroretentive System

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on SPARC1103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1103.

Explore the full profile